Becton Dickinson Q3 revenue beats on product launches

The company raised the midpoint of its full-year adjusted diluted EPS guidance to $12.62-$12.72 and said it expects full-year revenue growth toward the high end of its range.

Becton Dickinson maintained its full-year GAAP revenue growth outlook at low single-digit plus.

The company cited strong momentum across its Medical Essentials, Connected Care, BioPharma Systems and Interventional segments following its spin-off.

Recent product launches and collaborations, including a Vizient contract for CentroVena One and a semaglutide launch with EMS, contributed to segment performance.

Management also attributed margin expansion and adjusted EPS growth to disciplined execution and strategic capital allocation.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell".

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy".

Wall Street's median 12-month price target for Becton Dickinson and Co is $182.00, about 6.6% above its August 5 closing price of $170.66.

The stock recently traded at 13 times the next 12-month earnings, versus a P/E of 11 three months ago.

Becton Dickinson said fiscal third-quarter revenue rose 5.4%, beating analyst expectations, as adjusted earnings per share increased 4.9% and also topped estimates.